|
1
|
Wilhelmus MM, Otte-Höller I, Wesseling P,
de Waal RM, Boelens WC and Verbeek MM: Specific association of
small heat shock proteins with the pathological hallmarks of
Alzheimer's disease brains. Neuropathol Appl Neurobiol. 32:119–130.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Reitz C, Brayne C and Mayeux R:
Epidemiology of Alzheimer disease. Nat Rev Neurol. 7:137–152. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Golde TE: The Abeta hypothesis: Leading us
to rationally-designed therapeutic strategies for the treatment or
prevention of Alzheimer disease. Brain Pathol. 15:84–87. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Schenk D, Basi GS and Pangalos MN:
Treatment strategies targeting amyloid β-protein. Cold Spring Harb
Perspect Med. 2:a0063872012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Selkoe DJ and Hardy J: The amyloid
hypothesis of Alzheimer's disease at 25 years. EMBO Mol Med.
8:595–608. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lane RF, Shineman DW, Steele JW, Lee LB
and Fillit HM: Beyond amyloid: The future of therapeutics for
Alzheimer's disease. Adv Pharmacol. 64:213–271. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Obregon D, Hou H, Deng J, Giunta B, Tian
J, Darlington D, Shahaduzzaman M, Zhu Y, Mori T, Mattson MP and Tan
J: Soluble amyloid precursor protein-α modulates β-secretase
activity and amyloid-β generation. Nat Commun. 3:7772012.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
George-Hyslop S and Fraser PE: Assembly of
the presenilin γ-/ε-secretase complex. J Neurochem. 120 Suppl
1:S84–S88. 2012. View Article : Google Scholar
|
|
9
|
Zhang HM, Zhang X and Li Y: The regulation
of curcumin on the amyloidogentic pathaway of APP in Alzheimer's
disease. Chin Pharmacol Bull. 25:361–366. 2009.(In Chinese).
|
|
10
|
Grimm MO, Mett J, Stahlmann CP, Haupenthal
VJ, Zimmer VC and Hartmann T: Neprilysin and Aβ clearance: Impact
of the APP intracellular domain in NEP regulation and implications
in Alzheimer's disease. Front Aging Neurosci. 5:982013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang DS, Dickson DW and Malter JS:
Beta-Amyloid degradation and Alzheimer's disease. J Biomed
Biotechnol. 2006:584062006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kanemitsu H, Tomiyama T and Mori H: Human
neprilysin is capable of degrading amyloid beta peptide not only in
the monomeric form but also the pathological oligomeric form.
Neurosci Lett. 350:113–116. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kurochkin IV and Goto S: Alzheimer's
beta-amyloid peptide specifically interacts with and is degraded by
insulin degrading enzyme. FEBS Lett. 345:33–37. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hayes CD, Dey D, Palavicini JP, Wang H,
Patkar KA, Minond D, Nefzi A and Lakshmana MK: Striking reduction
of amyloid plaque burden in an Alzheimer's mouse model after
chronic administration of carmustine. BMC Med. 11:812013.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Eckman EA and Eckman CB: Abeta-degrading
enzymes: Modulators of Alzheimer's disease pathogenesis and targets
for therapeutic intervention. Biochem Soc Trans. 33:1101–1105.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Siemers ER, Sundell KL, Carlson C, Case M,
Sethuraman G, Liu-Seifert H, Dowsett SA, Pontecorvo MJ, Dean RA and
Demattos R: Phase 3 solanezumab trials: Secondary outcomes in mild
Alzheimer's disease patients. Alzheimers Dement. 12:110–120. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Turtle CJ, Hanafi LA, Berger C, Hudecek M,
Pender B, Robinson E, Hawkins R, Chaney C, Cherian S, Chen X, et
al: Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of
CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T
cells. Sci Transl Med. 8:355ra1162016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Dai Y, Ma T, Ren X, Wei J, Fu W, Ma Y, Xu
S and Zhang Z: Tongluo Xingnao Effervescent Tablet preserves
mitochondrial energy metabolism and attenuates cognition deficits
in APPswe/PS1De9 mice. Neurosci Lett. 630:101–108. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xu SJ, Dai Y, Zhang YJ, Xiong M, Ma YT and
Zhong ZD: Effects of tongluo xingnao effervescent tablet on
expression of CKD5 and GSK-3 in rat model of hippocampus with Aβ
injection. West China J Pharm Sci. 28:140. 2013.(In Chinese).
|
|
20
|
Zhang YJ, Ju SH, Hu Y, Ren XY and Xu SJ:
Effect of Tongluo Xingnao effervescent tablets on cerebral
cholinergic function of mice dementia model induced by scopolamine.
Tradit Chin Drug Res Pharmacol. 25:272–276. 2014.(In Chinese).
|
|
21
|
Zhang YJ, Dai Y, Hu Y, Ma YT, Xu SJ and
Wang YY: Effect of tongluo xingnao effervescent tablet on learning
and memory of AD rats and expression of insulin-degrading enzyme in
hippocampus. Zhongguo Zhong Yao Za Zhi. 38:2863–2867. 2013.(In
Chinese). PubMed/NCBI
|
|
22
|
Xu SJ and Dai Y: A pharmaceutical
composition for treating neurodegenerative diseases and its
preparation method and application CN Patent CN103181954A. Filed
April 12, 2013; issued July 3. 2013, (In Chinese).
|
|
23
|
Ren X, Wei J, Gong D, Hu Y, Chen H and Xu
S: Tongluoxingnao effervescent tablets ameliorate learning and
memory impairment in a rat model of vascular dementia via the
regulation of the p38 and ERK MAPK signaling pathways. Int J Clin
Exp Med. 9:5400–5412. 2016.
|
|
24
|
Institute of Laboratory Animal Resources
(US), Committee on Care and Use of Laboratory Animals, National
Institutes of Health (US), and Division of Research Resources, .
Guide for the care and use of laboratory animals. The National
Academies Press; Washington, DC: 1985
|
|
25
|
Buttini M, Masliah E, Barbour R, Grajeda
H, Motter R, Johnson-Wood K, Khan K, Seubert P, Freedman S, Schenk
D and Games D: Beta-amyloid immunotherapy prevents synaptic
degeneration in a mouse model of Alzheimer's disease. J Neurosci.
25:9096–9101. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li T, Li YM, Ahn K, Price DL, Sisodia SS
and Wong PC: Increased expression of PS1 is sufficient to elevate
the level and activity of γ-secretase in vivo. PLoS One.
6:e281792011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Grimm A, Friedland K and Eckert A:
Mitochondrial dysfunction: The missing link between aging and
sporadic Alzheimer's disease. Biogerontology. 17:281–296. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Selkoe DJ and Hardy J: The amyloid
hypothesis of Alzheimer's disease at 25 years. EMBO Mol Med.
8:595–608. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Izzo NJ, Staniszewski A, To L, Fa M, Teich
AF, Saeed F, Wostein H, Walko T III, Vaswani A, Wardius M, et al:
Alzheimer's therapeutics targeting Amyloid beta 1–42 oligomers I:
Abeta 42 oligomer binding to specific neuronal receptors is
displaced by drug candidates that improve cognitive deficits. PLoS
One. 9:e1118982014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sevigny J, Chiao P, Bussière T, Weinreb
PH, Williams L, Maier M, Dunstan R, Salloway S, Chen T, Ling Y, et
al: The antibody aducanumab reduces Aβ plaques in Alzheimer's
disease. Nature. 537:50–56. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang YJ, Zhou HD and Zhou XF: Clearance of
amyloid-beta in Alzheimer's disease: Progress, problems and
perspectives. Drug Discov Today. 11:931–938. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Liu XP, Qian X, Xie Y, Qi Y, Peng MF, Zhan
BC and Lou ZQ: Betaine suppressed Aβ generation by altering amyloid
precursor protein processing. Neurol Sci. 35:1009–1013. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Siemers ER, Quinn JF, Kaye J, Farlow MR,
Porsteinsson A, Tariot P, Zoulnouni P, Galvin JE, Holtzman DM,
Knopman DS, et al: Effects of a gamma-secretase inhibitor in a
randomized study of patients with Alzheimer disease. Neurology.
66:602–604. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Iwata N, Tsubuki S, Takaki Y, Watanabe K,
Sekiguchi M, Hosoki E, Kawashima-Morishima M, Lee HJ, Hama E,
Sekine-Aizawa Y and Saido TC: Identification of the major
Abeta1-42-degrading catabolic pathway in brain parenchyma:
Suppression leads to biochemical and pathological deposition. Nat
Med. 6:143–150. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
35
|
El-Amouri SS, Zhu H, Yu J, Gage FH, Verma
IM and Kindy MS: Neprilysin protects neurons against Abeta peptide
toxicity. Brain Res. 1152:191–200. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Marr RA, Rockenstein E, Mukherjee A, Kindy
MS, Hersh LB, Gage FH, Verma IM and Masliah E: Neprilysin gene
transfer reduces human amyloid pathology in transgenic mice. J
Neurosci. 23:1992–1996. 2003.PubMed/NCBI
|
|
37
|
Bulloj A, Leal MC, Surace EI, Zhang X, Xu
H, Ledesma MD, Castaño EM and Morelli L: Detergent resistant
membrane-associated IDE in brain tissue and cultured cells:
Relevance to Abeta and insulin degradation. Mol Neurodegener.
3:222008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Farris W, Mansourian S, Chang Y, Lindsley
L, Eckman EA, Frosch MP, Eckman CB, Tanzi RE, Selkoe DJ and
Guenette S: Insulin-degrading enzyme regulates the levels of
insulin, amyloid beta-protein, and the beta-amyloid precursor
protein intracellular domain in vivo. Proc Natl Acad Sci USA.
100:pp. 4162–4167. 2003; View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wu TY, Chen CP and Jinn TR: Traditional
Chinese medicines and Alzheimer's disease. Taiwan J Obstet Gynecol.
50:131–135. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Howes MJR and Houghton PJ: Plants used in
Chinese and Indian traditional medicine for improvement of memory
and cognitive function. Pharmacol Biochem Behav. 75:513–527. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Dos S, Antos-Neto LL, de Vilhena Toledo
MA, Medeiros-Souza P and de Souza GA: The use of herbal medicine in
Alzheimer's disease: a systematic review. Evid Based Complement
Alternat Med. 3:441–445. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zhang YJ, Xu SJ, Dai Y, Xiong M and Ma YT:
Effects of Tongluoxingnao Effervescent Tablet on synaptophysin of
injecting Aβ in the hippocampus rat model. Pharm Clin Chin Mat Med.
28:84–87. 2012.(In Chinese).
|
|
43
|
Ren XY, Hu Y, Wei JP, Ma YT and Xu SJ:
Effects of Tongluo Xingnao effervescent tablets on expression of
cytochrome C oxidase in cells in hippocampus of VD rat model. Chin
J Basic Med Tradit Chin Med. 2:159–161. 2015.(In Chinese).
|
|
44
|
Ren XY, Hu Y, Wei JP, Fu WJ, Xu SJ and
Wang YY: Effects of Tongluo Xingnao effervescent tablets on blood
rheology, iNOS, VEGF and LDH-5 in MID rats. Zhongguo Zhong Yao Za
Zhi. 41:1119–1123. 2016.(In Chinese). PubMed/NCBI
|
|
45
|
Huang H, Nie S, Cao M, Marshall C, Gao J,
Xiao N, Hu G and Xiao M: Characterization of AD-like phenotype in
aged APPSwe/PS1dE9 mice. Age (Dordr). 38:303–322. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Romberg C, Mattson MP, Mughal MR, Bussey
TJ and Saksida LM: Impaired attention in the 3xTgAD mouse model of
Alzheimer's disease: Rescue by donepezil (Aricept). J Neurosci.
31:3500–3507. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Stahl SM: The new cholinesterase
inhibitors for Alzheimer's disease, Part 1: Their similarities are
different. J Clin Psychiatry. 61:710–711. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Gandy S: The role of cerebral amyloid beta
accumulation in common forms of Alzheimer disease. J Clin Invest.
115:1121–1129. 2005. View Article : Google Scholar : PubMed/NCBI
|
